The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).
The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD). With these new patents, Suven has a total of twenty granted patents from Europe and eight granted patents from Macau. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.
"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for Major Depressive Disorder (MDD) with high unmet medical need with huge market potential globally” says Venkat Jasti, CEO of Suven.
Suven Life Sciences Ltd is currently trading at Rs. 272.6, up by Rs. 10.65 or 4.07% from its previous closing of Rs. 261.95 on the BSE.
The scrip opened at Rs. 263.85 and has touched a high and low of Rs. 275.2 and Rs. 260.45 respectively. So far 141225(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 3334.16 crore.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 338.5 on 15-Apr-2015 and a 52 week low of Rs. 192.15 on 08-Sep-2015. Last one week high and low of the scrip stood at Rs. 273.2 and Rs. 254.4 respectively.
The promoters holding in the company stood at 59.57 % while Institutions and Non-Institutions held 7.2 % and 33.23 % respectively.
The stock is currently trading below its 50 DMA.
No comments:
Post a Comment